Missouri State Senate

House Amendment

HCS/SB 284 - This act exempts from state and local sales tax all sales of diabetic accessories and supplies, and rented medical oxygen, wheelchairs, scooters, reading machines, electronic print enlargers, electronic communication devices, and items used to modify motor vehicles for individuals with disabilities. The act also modifies the sales tax exemption for nonprescription drugs, so that nonprescription drugs prescribed by a practitioner are exempt. Any medical equipment, supplies, or devices that are ordered by a doctor, or paid for by a third-party insurer, Medicare, or Medicaid, will also be exempt from these taxes.

This act allows the Board of Pharmacy to refuse to issue a certificate of registration, permit, or license to an applicant for a pharmacy or drug distributor license if the designated pharmacist-in-charge, manager-in-charge, or any officer, owner, manager, or controlling shareholder of the applicant has committed an act that would be grounds for discipline under the Board of Pharmacy's disciplinary statute.

This act defines the term "legend drug" for the purpose of certain pharmacy laws. Legend drugs will mean any drug or biological product that is subject to a certain federal law, is required to be labeled in certain ways, or is required to be dispensed by prescription only or is restricted to use by practitioners only. The act excludes certain drugs and drug products that are being used in clinical trials.

This act has an emergency clause for the section regarding legend drugs.

This act is similar to HB 55 (2011) and HB 412 (2011).

EMILY KALMER

HA 1 - UNDER THIS AMENDMENT, ANY HEALTH BENEFIT PLAN THAT PROVIDES COVERAGE AND BENEFITS FOR CANCER CHEMOTHERAPY TREATMENT SHALL NOT REQUIRE A HIGHER COPAYMENT, DEDUCTIBLE, OR COINSURANCE AMOUNT FOR A PRESCRIBED, ORALLY ADMINISTERED ANTICANCER MEDICATION THAT IS USED TO KILL OR SLOW THE GROWTH OF CANCEROUS CELLS THAN WHAT THE PLAN REQUIRES FOR AN INTRAVENOUSLY ADMINISTERED OR INJECTED CANCER MEDICATION THAT IS PROVIDED, REGARDLESS OF FORMULATION OR BENEFIT CATEGORY DETERMINATION BY THE HEALTH CARRIER ADMINISTERING THE HEALTH BENEFIT PLAN. A HEALTH CARRIER SHALL NOT ACHIEVE COMPLIANCE WITH THE PROVISIONS OF THE ACT BY IMPOSING AN INCREASE IN COPAYMENT, DEDUCTIBLE, OR COINSURANCE AMOUNT FOR AN INTRAVENOUSLY ADMINISTERED OR INJECTED CANCER CHEMOTHERAPY AGENT COVERED UNDER THE HEALTH BENEFIT PLAN. COVERAGE UNDER THIS AMENDMENT IS LIMITED TO FEDERAL DRUG ADMINISTRATION APPROVED INDICATIONS AND NATIONAL COMPREHENSIVE CANCER NETWORK RECOMMENDATIONS AND MAY BE ADMINISTERED BY A SPECIALTY PHARMACY NETWORK.

HyperLink